Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group

Cancer. 1989 Apr 15;63(8):1457-65. doi: 10.1002/1097-0142(19890415)63:8<1457::aid-cncr2820630802>3.0.co;2-j.

Abstract

The Childrens Cancer Study Group conducted four therapeutic studies on a total of 1006 children with acute nonlymphocytic leukemia from 1972 to 1983. This report describes the therapeutic strategies of these studies and examines trends in induction rates and long-term outcome over this period. The remission induction rate has changed from 58% in 1972 to 1975 to 80% for the period 1980 to 1983, and the induction mortality dropped from 20% to 6%. Four-year survival probabilities from time of diagnosis have almost doubled from 19% to 36%. Few deaths occurred more than 5 years after diagnosis: children surviving in first remission beyond 5 years had a 92% survival rate and an 86% relapse-free survival rate over the next 5 years. In contrast, median survival after a marrow relapse was less than 6 months and the 6-year survival probability was 4%. The leukocyte count was a significant prognostic factor, and although the mortality for infants was high initially, long-term survival was not decreased.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Female
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy*
  • Leukocyte Count
  • Male
  • Prednisolone / administration & dosage
  • Prognosis
  • Remission Induction
  • Thioguanine / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Vincristine
  • Cyclophosphamide
  • Prednisolone
  • Thioguanine
  • Azacitidine
  • Daunorubicin

Supplementary concepts

  • D-ZAPO protocol
  • PATCO protocol